8-K: Larimar Therapeutics Advances Nomlabofusp Development with FDA START Program and Positive Clinical Data

Larimar Therapeutics is progressing its lead candidate, nomlabofusp, for Friedreich's ataxia, with positive clinical trial results and participation in the FDA's START pilot program.

Summary

• Larimar Therapeutics is focused on developing nomlabofusp (CTI-1601), a protein replacement therapy for Friedreich's ataxia (FA).
• Nomlabofusp is designed to deliver frataxin protein directly to the mitochondria, addressing the underlying cause of FA.
• The company has completed a Phase 2 study showing dose-dependent increases in frataxin levels in skin and buccal cells.
• Larimar has initiated an open-label extension (OLE) study with 25 mg daily dosing, with interim data expected in Q4 2024.
• The FDA has removed a partial clinical hold on the program and selected nomlabofusp for its START pilot program.
• The company plans to escalate the dose to 50 mg following further characterization of frataxin pharmacodynamics at the 25 mg dose.
• Larimar has approximately $239 million in cash and investments as of March 31, 2024, providing a cash runway into 2026.
• A Biologics License Application (BLA) submission is targeted for the second half of 2025.
• The company is also exploring the use of frataxin levels as a surrogate endpoint to support accelerated approval.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, regulatory support, and a solid financial position. The company is making significant progress towards its goals, and the risks are well-managed.

Positives

• Nomlabofusp has shown consistent positive results in Phase 1 and Phase 2 trials, with dose-dependent increases in frataxin levels.
• The FDA's START program selection and removal of the partial clinical hold are strong endorsements of the program.
• The company has a strong financial position with a cash runway into 2026.
• Nomlabofusp has received Orphan Drug, Rare Pediatric Disease, Fast Track, and PRIME designations.
• The company has a strong intellectual property portfolio with a composition of matter patent extending into 2040.
• The open-label extension study is underway with near-term catalysts expected.
• Nomlabofusp is generally well tolerated at doses tested up to 4 weeks.

Negatives

• One Phase 2 participant withdrew due to an allergic reaction, which resolved with standard treatment.
• One Phase 1 participant withdrew due to mild-to-moderate nausea and vomiting.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval.

Risks

• Clinical trial results may differ from earlier data, and the FDA may not agree with the development strategy.
• The company's ability to raise capital and obtain regulatory approvals is subject to risks and uncertainties.
• Manufacturing and scaling of nomlabofusp may present challenges.
• Public health crises and general economic conditions could impact clinical trials and operations.
• There is a risk that the company may not be able to successfully commercialize nomlabofusp.

Future Outlook

Larimar intends to pursue accelerated approval for nomlabofusp with a potential BLA submission targeted for the second half of 2025. The company is also planning to expand its clinical program to ex-U.S. geographies and is discussing with the FDA the potential use of FXN levels to support accelerated approval.

Management Comments

• The company is continuing to enroll patients and activate additional sites for the OLE study.
• Discussions to support an accelerated approval are ongoing with the FDA.
• The company is beginning preparations to expand the nomlabofusp clinical program to ex-U.S. geographies.

Industry Context

This announcement is significant as it highlights the progress of a potential first-in-class protein replacement therapy for Friedreich's ataxia, a rare and debilitating disease with limited treatment options. The FDA's START program selection underscores the unmet need and the potential of nomlabofusp. The competitive landscape includes other approaches such as mitochondrial oxidative stress modifiers, gene expression regulators, and gene therapies, but nomlabofusp is differentiated by its direct protein replacement mechanism.

Comparison to Industry Standards

• The document mentions Omaveloxolone (SKYCLARYS) by Reata Pharma/Biogen as an approved treatment for FA, but it does not address the underlying frataxin deficiency like nomlabofusp.
• Other companies like PTC Therapeutics and Design Therapeutics are developing treatments for FA, but they are at different stages of development.
• Lexeo Therapeutics is developing a gene therapy for FA, which is a different approach than Larimar's protein replacement therapy.
• The document highlights that nomlabofusp is a potential first-and-only protein replacement therapy designed to address the underlying cause of FA, which differentiates it from other treatments in development.

Stakeholder Impact

• Shareholders: The positive clinical data and regulatory progress are likely to be viewed favorably by investors.
• Patients: The development of nomlabofusp offers hope for a potential treatment for Friedreich's ataxia.
• Employees: The company's progress and financial stability provide a positive outlook for employees.
• Analysts: The company's progress and financial stability provide a positive outlook for analysts.
• Creditors: The company's strong financial position reduces the risk for creditors.

Next Steps

• Continue enrolling patients and activating additional sites for the open-label extension study.
• Further characterize frataxin pharmacodynamics at the 25 mg dose and plan dose escalation to 50 mg.
• Present final Phase 2 data at a conference in the second half of 2024.
• Submit a Biologics License Application (BLA) in the second half of 2025.
• Expand the nomlabofusp clinical program to ex-U.S. geographies.

Key Dates

Keywords

nomlabofusp, Friedreich's ataxia, frataxin, FDA START program, clinical trials, protein replacement therapy, rare disease, accelerated approval, BLA submission, mitochondria